In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN.
Manguso RT, et al. Among authors: doench jg.
Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270. Epub 2017 Jul 19.
Nature. 2017.
PMID: 28723893
Free PMC article.